Navigation Links
Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
Date:3/4/2013

treatments for multiple types of patients," said Peter Piliero , MD, vice president, Clinical and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc. "These new data add to our expanding body of clinical evidence on faldaprevir as we continue to pursue HCV treatment options for a diverse range of patients that physicians frequently encounter in clinical practice."

About STARTVerso™ 4

STARTVerso™ 4 is an open-label, sponsor blinded, Phase 3 study assessing the efficacy and safety of Boehringer Ingelheim's investigational oral protease inhibitor faldaprevir in combination with PegIFN/RBV. The study includes 308 individuals co-infected with HCV and HIV who were treatment-naive (TN) or had relapsed after previous HCV therapy with PegIFN/RBV, and were either HIV treatment-naive or being treated with ART. The trial includes patients with cirrhosis (17% had F4 cirrhosis or Fibroscan >13 kPa).

  • Group 1: 12 or 24 weeks of faldaprevir 240mg once-daily in addition to 24 or 48 weeks of PegIFN/RBV
  • Group 2: 24 weeks of faldaprevir 120mg once-daily in addition to 24 or 48 weeks of PegIFN/RBV

About Boehringer Ingelheim in Hepatitis C Virus (HCV)

In partnership with the scientific community, our clinical trial program, HCVerso™, is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. The ongoing multi-study Phase 3 STARTVerso™ trial program, evaluating faldaprevir combined with PegIFN/RBV in treatment-naive, treatment-experienced and HIV co-infected patients with chronic genotype-1 HCV, is near clinical completion. BI 207127 is an investigational NS5B non-nucleoside polymerase in
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
2. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
3. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
4. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
5. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
8. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
9. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
10. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
11. Boehringer Ingelheim Announces Equine Research Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... May 24, 2013  Regulatory and marketplace changes ... many organizations, priority list. Forward-thinking ... understand a strong Medical Affairs function ... development, market education , and regulatory compliance. ... vital bridge between an organization and one of ...
(Date:5/24/2013)... LAKES, N.J. , May 24, 2013  BD (Becton, ... global medical technology company, announced today that it will present ... Conference on Thursday, May 30, 2013, at 10:40 a.m. (ET). ... be accessed from the BD corporate website at www.bd.com/investors ... 6, 2013.    About BD BD ...
(Date:5/24/2013)... BEVERLY HILLS, Calif. , May 24, 2013 /PRNewswire-iReach/ ... the state,s leading non-profit substance abuse services organization, is ... at the Beverly Hills Hotel on June 6, 2013.  ... event to raise funds for the adolescent residential treatment ... as well as honor individuals whose accomplishments have positive ...
Breaking Medicine Technology:Building Medical Affairs Capabilities to Ensure Organizational Success across Key Operational Areas 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 2Phoenix House Honors Allergan Chairman David Pyott And Legendary Sports Agent And Humanitarian, Leigh Steinberg 3
... 19 Encorium Group, Inc. (Nasdaq: ENCO ), (the ... in over 30 countries for many of the world,s leading pharmaceutical ... AG, a corporation organized in Switzerland and its wholly-owned ... , Chile , Switzerland , India and ...
... Corgenix Medical Corporation (OTC Bulletin Board: CONX), a worldwide developer ... Paris, France -based, privately held group of companies and worldwide manufacturer and ... alliance. Terms of the agreement include: , ... Strategic Investment – ELITech will ...
Cached Medicine Technology:Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO 2Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO 3Encorium Group, Inc. Acquires Progenitor International Research, a Vaccine Focused Emerging Market CRO 4Corgenix Medical Corp. and the ELITech Group Establish Strategic Alliance 2Corgenix Medical Corp. and the ELITech Group Establish Strategic Alliance 3Corgenix Medical Corp. and the ELITech Group Establish Strategic Alliance 4
(Date:5/25/2013)... Springs, FL (PRWEB) May 25, 2013 ... Dallas-Ft. Worth, Texas. It is the fifth largest media market ... Dallas is the number one visitor destination in Texas and ... cultural gateway to the American West as it is home ... activities everyone will enjoy from sports to the arts. Residents ...
(Date:5/25/2013)... May 25 (HealthDay News) -- Many viruses and parasites ... and leptospirosis -- a bacteria-borne illness than can result ... at dog parks, according to a veterinarian. ... and even the air, said Dr. Susan Nelson, a ... Center. "Many of these serious diseases can be fatal, ...
(Date:5/25/2013)... 25, 2013 Radius Engineering International ... company in the US and has been building ... over 35 years. M.E. and President, Walton McCarthy, ... NBC Weapon Fundamentals and Shelter Engineering Standards, Sixth ... on shelter engineering. McCarthy is considered the leading ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 Absolute Surgical Specialists, ... many of the NALA’s businesses throughout the country participating in ... to participate in the nationwide event as he understands what ... Colonel in the Army. He said, “I wanted to give ... I serve, but I live here too.” , Shop Local ...
(Date:5/25/2013)... (PRWEB) May 25, 2013 The ... ranging from irritable bowel syndrome (IBS) to bloating, ... among the most long-lasting, embarrassing, frustrating and difficult ... foods for digestive health have provided a ... are many factors contributing to digestive health issues, ...
Breaking Medicine News(10 mins):Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2
... acts in New York and Washington DC, air transportation ... several days, which severely affected the production and distribution ... due to their specific nature. These products are either ... component, and are used in diagnosis or therapy based ...
... your diet can affect your vision, according to a new ... of the eye causing fuzziness, shadows and severe visual impairment. ... diet has been implicated in its development. // ... a study of 349 individuals aged 55 to 80 with ...
... about the dramatic rise in overseas drug testing and ... experimental medicines and Americans who buy products based on ... outside the United States who voluntarily report their experiments ... dwarfing the agency's ability to inspect the test sites. ...
... by high rates of relapse, even after prolonged drug abstinence. ... Medical Center in the Netherlands and the intramural laboratories of ... process in the brain that may lead to a new ... // , In studies using rats, the ...
... Newborns are more likelier to develop a serious ... antibiotic erythromycin, say US scientists., ,A research team ... to pyloric stenosis, a condition that affects about 1 ... cause of abdominal surgery in infants. ,Using ...
... of drug-resistant E. coli has emerged as a possible ... a normal inhabitant of the digestive tract that can ... E. coli from bad food is a frequent cause ... were thought until now to result mostly from inadvertent ...
Cached Medicine News: